Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10323716" target="_blank" >RIV/00064203:_____/16:10323716 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00089256 RIV/00216208:11130/16:10323716 RIV/65269705:_____/16:00064628 RIV/00023736:_____/16:00011322

Výsledek na webu

<a href="http://dx.doi.org/10.1111/ejh.12587" target="_blank" >http://dx.doi.org/10.1111/ejh.12587</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ejh.12587" target="_blank" >10.1111/ejh.12587</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia

Popis výsledku v původním jazyce

ObjectiveTo evaluate the prognostic power of minimal residual disease (MRD) monitored by polymerase chain reaction at defined time points during early treatment in adult patients with acute lymphoblastic leukemia (ALL). MethodsSeventy-one patients were treated according to the GMALL 07/2003 protocol and evaluated for MRD in bone marrow by specific clonal rearrangements of Ig/TCR in BCR-ABL negative ALL or fusion gene transcript in BCR-ABL positive ALL. ResultsThree-year overall survival (OS) was 94% in patients with BCR-ABL negative ALL reaching complete molecular response (CMR) after the first course of chemotherapy (vs. 32% if MRD >10(-4); P=0.001). Patients with CMR prior to the start of consolidation chemotherapy at week 11 had 3-yr OS 82% (vs. 18% if MRD >10(-4); P=0.001). Patients with BCR-ABL positive ALL showed slower MRD dynamics. There was a trend to better OS in patients with 4 log reduction of BCR-ABL transcript prior to HSCT (92% vs. 50%; P=0.065). None of the patients with detectable MRD (both BCR-ABL positive and negative) after HSCT survived 3yr. ConclusionEarly MRD kinetics is an important tool for new prognostication models with direct clinical impact irrespective of standard prognostic factors in patients with BCR-ABL negative ALL.

Název v anglickém jazyce

Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia

Popis výsledku anglicky

ObjectiveTo evaluate the prognostic power of minimal residual disease (MRD) monitored by polymerase chain reaction at defined time points during early treatment in adult patients with acute lymphoblastic leukemia (ALL). MethodsSeventy-one patients were treated according to the GMALL 07/2003 protocol and evaluated for MRD in bone marrow by specific clonal rearrangements of Ig/TCR in BCR-ABL negative ALL or fusion gene transcript in BCR-ABL positive ALL. ResultsThree-year overall survival (OS) was 94% in patients with BCR-ABL negative ALL reaching complete molecular response (CMR) after the first course of chemotherapy (vs. 32% if MRD >10(-4); P=0.001). Patients with CMR prior to the start of consolidation chemotherapy at week 11 had 3-yr OS 82% (vs. 18% if MRD >10(-4); P=0.001). Patients with BCR-ABL positive ALL showed slower MRD dynamics. There was a trend to better OS in patients with 4 log reduction of BCR-ABL transcript prior to HSCT (92% vs. 50%; P=0.065). None of the patients with detectable MRD (both BCR-ABL positive and negative) after HSCT survived 3yr. ConclusionEarly MRD kinetics is an important tool for new prognostication models with direct clinical impact irrespective of standard prognostic factors in patients with BCR-ABL negative ALL.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: CEITEC - central european institute of technology</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Haematology

ISSN

0902-4441

e-ISSN

—

Svazek periodika

96

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

DK - Dánské království

Počet stran výsledku

9

Strana od-do

276-284

Kód UT WoS článku

000370346800009

EID výsledku v databázi Scopus

2-s2.0-84958114240